ClinicalTrials.gg
RecruitingNCT05384158Updated Aug 28, 2026

Valuation in Depressed Mood, Anhedonia, and Anxiety

An interventional study of cognitive behavioral therapy and valuation with instruction in Neurobehavioral Components of Reward and Loss Valuation, sponsored by Virginia Polytechnic Institute and State University. Recruiting at 1 site in United States. Open to participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Aug 2021, registered May 2022).
  • Started Aug 2021; still recruiting 5 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
25 Years to 50 Years
Sex
All
01

Study summary

This study examines how people respond to rewards and losses, and the extent to which these responses are linked or distinct among people experiencing depressed mood, anhedonia, and/or anxiety.

Read the detailed description

This study tests relationships among neural and behavioral valuation mechanisms, and how these mechanisms change (or not) over time, with task instructions, and following cognitive behavior therapy.

02

Conditions studied

  • Neurobehavioral Components of Reward and Loss Valuation

Keywords

  • depression
  • anxiety
  • anhedonia
03

In context

Depression

8,577 studies on the registry are indexed under Depression; 1,720 are open to participants now.

This study's planned enrollment of 252 is above the median of 81 across 7,063 interventional studies indexed under Depression.

Browse Depression studies →

Lead sponsor

Virginia Polytechnic Institute and State University is the lead sponsor of 127 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • mood, anxiety, or anhedonia symptoms that affect functioning; fluent in English; able to see computer display; able to perform simple computer games.

Exclusion criteria

Exclusion Criteria:

  • history of seizure disorder, stroke, or head injury with more than 10 minutes of unconsciousness; hormone disorder; electroconvulsive therapy within 5 years; history of chemotherapy for cancer; current pregnancy; to MRI
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Active comparator
    Cognitive behavioral therapy

    cognitive behavioral therapy for depression, anxiety, and/or anhedonia

    Behavioral: cognitive behavioral therapy

  • Active comparator
    Valuation with instruction

    repeat laboratory sessions of a reward/loss learning computer game with specific instructions

    Behavioral: valuation with instruction

  • Active comparator
    Valuation without instruction

    repeat laboratory sessions of a reward/loss learning computer game without specific instructions

    Behavioral: valuation without instruction

Interventions

  • Behavioralcognitive behavioral therapy

    cognitive behavioral therapy

  • Behavioralvaluation with instruction

    repeat laboratory sessions of computerized learning game

  • Behavioralvaluation without instruction

    repeat laboratory sessions of computerized learning game

06

What researchers measure

Primary outcomes

  1. change in proportion correct on the 'N-arm bandit learning task'

    change in proportion correct on 'N-arm bandit reinforcement learning task' from study entrance to study exit

    Time frame: study entrance to study exit, an average of 12 weeks

Secondary outcomes

  1. change in depression symptoms (Beck Depression Inventory)

    change in depression symptoms from study entrance to study exit

    Time frame: study entrance to exit, an average of 12 weeks

  2. change in anxiety symptoms (anxiety subscale; Mood and Anxiety Symptom Questionnaire)

    change in anxiety symptoms from study entrance to study exit

    Time frame: study entrance to exit, an average of 12 weeks

  3. change in anhedonia symptoms (anhedonia subscale; Mood and Anxiety Symptom Questionnaire)

    change in anhedonia symptoms from study entrance to study exit

    Time frame: study entrance to exit, an average of 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Jul 2027, 71 months after the start.

Of 3,468 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 71 months is above that.

Counting every sponsor, half of 3,566 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2022
First posted
May 20, 2022
StartActual
Aug 1, 2021
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05384158
Responsible party
Pearl Chiu (Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
May 20, 2022
Start date
Aug 1, 2021
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion